LOG IN
SIGN UP
News
AEZS
2.490
-7.09%
-0.190
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aeterna Zentaris (AEZS), Delcath Systems (DCTH) and GlaxoSmithKline (GSK)
TipRanks · 3d ago
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/23 13:25
Aeterna Zentaris GAAP EPS of -$2.56, revenue of $2.5M
Seeking Alpha · 03/23 12:39
BRIEF-Aeterna Zentaris Inc - QTRLY Net Loss Of $12.5 Million, Or $2.56 Loss Per Common Share
Reuters · 03/23 12:22
AEterna Zentaris Q4 Sales $2.50M Beat $1.06M Estimate
Benzinga · 03/23 12:13
Aeterna stock rises ~10% after Pharmanovia acquires rights to Ghryvelin in EU, UK
Seeking Alpha · 03/16 12:39
Inhibrx, Inc. (INBX) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 03/06 22:35
Are Medical Stocks Lagging IDEXX Laboratories (IDXX) This Year?
NASDAQ · 02/23 14:40
Alkermes (ALKS) Q4 Earnings & Sales Top Estimates, Stock Up
NASDAQ · 02/17 17:24
Analysts Offer Insights on Healthcare Companies: Aeterna Zentaris (AEZS), Arrowhead Pharmaceuticals (ARWR) and Enlivex (ENLV)
TipRanks · 01/23 11:20
Aeterna Zentaris Shelves Early-Stage Vaccine Programs, Including COVID-19
Benzinga · 01/17 17:53
BRIEF-Aeterna Zentaris Provides Business Update
Reuters · 01/17 13:53
Aeterna Zentaris (AEZS) Reports Q3 Loss, Tops Revenue Estimates
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -2.94% and 38.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/03/2022 14:15
Aeterna Zentaris GAAP EPS of -$0.70 misses by $0.02, revenue of $1.9M beats by $0.57M
Seekingalpha · 11/03/2022 13:02
AEterna Zentaris Q3 EPS $(0.70) Down From $(0.25) YoY
Benzinga · 11/03/2022 12:25
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
– Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS) (“Aet...
GlobeNewswire · 11/03/2022 12:05
Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk
Aeterna Zentaris (NASDAQ:AEZS) on Monday said it would rega...
Seekingalpha · 08/29/2022 14:12
BRIEF-Aeterna Zentaris Set To Regain Full Rights To Macrilen In U.S. And Canada From Novo Nordisk
BRIEF-Aeterna Zentaris Set To Regain Full Rights To Macrilen In U.S. And Canada From Novo Nordisk
Reuters · 08/29/2022 12:07
Aeterna Zentaris Set To Regain Full Rights To Macrilen In U.S. And Canada From Novo Nordisk
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced
Benzinga · 08/29/2022 12:06
BRIEF-Aeterna Zentaris Reports Q2 Rev Negative $0.2 Mln
BRIEF-Aeterna Zentaris Reports Q2 Rev Negative $0.2 Mln
Reuters · 08/03/2022 21:55
More
Webull provides a variety of real-time AEZS stock news. You can receive the latest news about Aeterna Zentaris Inc through multiple platforms. This information may help you make smarter investment decisions.
About AEZS
Aeterna Zentaris Inc. is a specialty biopharmaceutical company, which is engaged in commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The Company focuses on the commercialization of macimorelin in Asia and the rest of the world.